Rep. Colin Z. Allred

Maddy summaryHR 3443, the Foster Youth Mentoring Act of 2023, creates a federal grant program to fund structured mentoring programs for youth in foster care and those who have aged out of foster care (under age 26). The bill authorizes $50 million annually for grants to eligible organizations (like nonprofits, state agencies, or tribes) to establish or expand mentoring that provides consistent, year-long relationships focused on academic support, emotional development, and transition to adulthood. Key requirements include mandatory mentor training on trauma, cultural competence, and child welfare coordination, along with strict background checks and recruitment strategies to reflect the diversity of youth served. The program directly affects approximately 443,000 youth in foster care (per 2017 data) and aims to improve their educational outcomes, reduce school absences, and build supportive connections through evidence-based mentoring.

Maddy summaryThis bill changes Medicare coverage for colorectal cancer screenings. It eliminates out-of-pocket coinsurance costs for these screenings starting in 2026, requiring Medicare to cover 100% of the cost instead of the previous 85% for that year. The change applies to all subsequent years and directly affects Medicare beneficiaries seeking routine colorectal cancer screenings. The key provision amends Medicare Part B to remove the coinsurance requirement for these specific preventive services.

Maddy summaryThis bill establishes a new workplace violence prevention standard for healthcare and social service workers. It requires employers in covered facilities - including hospitals, nursing homes, mental health clinics, and social service settings - to develop and implement comprehensive prevention plans with specific requirements. These plans must include risk assessments, hazard prevention measures, employee training on violence prevention, and procedures for reporting and investigating violent incidents. The bill also amends Medicare regulations to require compliance with these standards for hospitals and skilled nursing facilities receiving Medicare funds.

Maddy summaryThe PROTECT 340B Act of 2023 prohibits pharmacy benefit managers (PBMs), health insurance plans, and health insurance issuers from discriminating against healthcare providers participating in the 340B drug pricing program. It specifically bans these entities from paying less for 340B drugs than they would for similar drugs dispensed by non-340B providers, imposing special requirements on 340B providers, or requiring identification of 340B drugs in billing. The bill establishes civil penalties of up to $5,000 per violation per day for PBMs that violate these protections and requires the Health Resources and Services Administration to create implementing regulations. It directly affects safety-net hospitals, clinics, and health centers that serve low-income patients, particularly those in rural areas, by protecting their ability to use 340B drug discounts to provide affordable care.

Maddy summaryHR 2474, the "Strengthening Medicare for Patients and Providers Act," changes how Medicare pays physicians for services. It replaces the previous two-part payment system (used through 2025) with a single annual payment rate update starting in 2024. This update will be based on the Medicare Economic Index (MEI), which tracks costs for medical providers. The change directly affects Medicare-certified doctors and clinics who receive payments under the physician fee schedule.

Maddy summaryThis bill would require Medicare to cover FDA-approved blood tests that screen for multiple cancers simultaneously (like breast, lung, or colorectal cancer) for beneficiaries. It directly affects Medicare recipients aged 65+ who could access these new screenings once per year, without prior authorization. The key provision adds "multi-cancer early detection screening tests" to Medicare's covered services under Part B, defining them as blood tests analyzing cell-free DNA, while maintaining existing coverage for standard screenings like mammograms. The bill does not change current coverage for individual cancer screenings but ensures Medicare keeps pace with new medical technology.

Maddy summaryHR 1692, the Health Care Affordability Act of 2023, adjusts how health insurance subsidies are calculated for people buying coverage through the marketplace. It replaces the previous subsidy formula with a sliding scale based on income, where households earning up to 150% of the poverty line pay 0% of premiums, and those at 400% or more pay 8.5%. The change applies to all income tiers between these points, with percentages increasing incrementally (e.g., 2% for 150-200% income). This directly affects individuals purchasing health insurance through the marketplace who qualify for subsidies under the Affordable Care Act. The bill amends Section 36B of the Internal Revenue Code and takes effect for tax years beginning after December 31, 2022.

Maddy summaryThis bill requires private health insurance plans and Medicaid to cover selected insulin products for individuals under 26 years old without deductibles and with cost-sharing capped at $35 per 30-day supply or 25% of the negotiated price (whichever is lower). It defines "selected insulin products" as at least one of each type (e.g., rapid-acting, long-acting) and form (e.g., vial, pump) of insulin that plans select. The cost-sharing for these products counts toward the plan’s annual out-of-pocket maximum, and the requirement applies to all private plans and Medicaid starting January 1, 2024. Plans are not required to cover insulin from out-of-network providers at the same cost-sharing level.

Maddy summaryThe Affordable Insulin Now Act (HR 1488) requires health insurance plans and issuers to cover specific insulin products with cost-sharing capped at $35 per 30-day supply or 25% of the negotiated price, whichever is lower, starting in 2024. It directly affects people with diabetes who rely on insulin by limiting out-of-pocket costs for covered products. The bill mandates coverage of all insulin types (rapid-acting, long-acting, etc.) and dosage forms (vials, pumps, etc.) as selected by the plan. This applies to both group and individual health insurance plans under the Public Health Service Act, Internal Revenue Code, and ERISA, with cost-sharing counting toward annual deductibles.

Maddy summaryThis bill expands Medicare coverage for hereditary cancer prevention and management. It requires Medicare to cover genetic testing for individuals with a personal or family history of hereditary cancer mutations, as defined by evidence-based guidelines from organizations like the National Comprehensive Cancer Network. The bill also mandates coverage for risk-reducing surgeries (like mastectomies or oophorectomies) when medically appropriate, and increases the frequency of recommended cancer screenings (such as mammograms, colonoscopies, and breast MRI) to at least annually for those with confirmed hereditary cancer gene mutations. These changes apply to Medicare beneficiaries with specific hereditary cancer risk factors, effective upon the bill's enactment.